Matrix metalloproteinases and their inhibitors: Promising novel biomarkers in severe sepsis?

Critical Care

Volumn 13, Issue 6, 2009, Pages

  Hoffmann, Ursula ^a   Brueckmann, Martina ^a   Borggrefe, Martin ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

GELATINASE B; STROMELYSIN 2; TISSUE INHIBITOR OF METALLOPROTEINASE 1; BIOLOGICAL MARKER; MATRIX METALLOPROTEINASE; TISSUE INHIBITOR OF METALLOPROTEINASE;

CORONARY ARTERY DISEASE; DISEASE MARKER; DISEASE SEVERITY; ENZYME BLOOD LEVEL; HEART FAILURE; HUMAN; INTENSIVE CARE UNIT; LUNG DISEASE; NEOPLASM; NOTE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; RHEUMATOID ARTHRITIS; SEPSIS; ANIMAL; DRUG ANTAGONISM; ENZYMOLOGY; HOMEOSTASIS; HOSPITALIZATION; METABOLISM; MORTALITY; MOUSE; MOUSE MUTANT; PREDICTION AND FORECASTING; SECRETION;

ANIMALS; BIOLOGICAL MARKERS; HOMEOSTASIS; HUMANS; MATRIX METALLOPROTEINASE 10; MATRIX METALLOPROTEINASE 9; MATRIX METALLOPROTEINASES; MICE; MICE, KNOCKOUT; PREDICTIVE VALUE OF TESTS; SEPSIS; SEVERITY OF ILLNESS INDEX; TISSUE INHIBITOR OF METALLOPROTEINASES;

EID: 77951630997     PISSN: 13648535     EISSN: 1466609X     Source Type: Journal    
DOI: 10.1186/cc8156     Document Type: Note

References (16)

1. Lorente L, Martin MM, Labarta L, Diaz C, Solé-Violán J, Blanquer J, Orbe J, Rodriguez JA, Jiménez A, Borreguero-Léon JM, Belmonte F, Medina JC, LLiminana MC, Ferrer-Agüero JM, Ferreres J, Mora ML, Lubillo S, Sánchez M, Barrios Y, Sierra A, Páramo JA. Matrix metalloproteinase-9, -10, and tissue inhibitor of matrix metal-loproteinases-1 blood levels as biomarkers of severity and mortality in sepsis. Crit Care 2009, 13:R158. 2784384, 19799791, 10.1186/cc8115.
2. Opdenakker G, Steen PHE, Van Damme J. Gelatinase B: a tuner and amplifier of immune functions. Trends Immunol 2001, 22:571-579. 10.1016/S1471-4906(01)02023-3, 11574282.
3. Elkington PTG, O'Kane CM, Friedland JS. The paradox of matrix metalloproteinases in infectious disease. Clin Exp Immunol 2005, 142:12-20. 1809491, 16178851, 10.1111/j.1365-2249.2005.02840.x.
4. Pugin J, Widmer MC, Kossodo S, Liang CM, Preas HL, Suffredini AF. Human neutrophils secrete gelatinase B in vitro and in vivo in response to endotoxin and proinflammatory mediators. Am J Respir Cell Mol Biol 1999, 20:458-464.
5. Chromek M, Tullus K, Lundahl J, Brauner A. Tissue inhibitor of metalloproteinase 1 activates normal human granulocytes, protects them from apoptosis, and blocks their transmigration during inflammation. Infect Immun 2004, 72:82-88. 343974, 14688084, 10.1128/IAI.72.1.82-88.2004.
6. Kotyza J, Pesek M, Puzman P, Havel D. Progelatinase B/matrix metalloproteinase-9 proenzyme as a marker of pleural inflammation. Exp Lung Res 2004, 30:297-309. 10.1080/01902140490276393, 15204835.
7. Ferroni P, Basili S, Martini F, Cardarello CM, Ceci F, Di Franco M, Bertazzoni G, Gazzaniga PP, Alessandri C. Serum metalloproteinase 9 levels in patients with coronary artery disease: a novel marker for inflammation. J Investig Med 2003, 51:295-300. 10.2310/6650.2003.3563, 14577520.
8. Yassen KA, Galley HF, Webster NR. Matrix metalloproteinase-9 concentrations in critically ill patients. Anaesthesia 2001, 56:729-732. 10.1046/j.1365-2044.2001.02083.x, 11493234.
9. Hoffmann U, Bertsch T, Dvortsak E, Liebetrau C, Lang S, Liebe V, Huhle G, Borggrefe M, Brueckmann M. Matrix-metalloproteinases and their inhibitors are elevated in severe sepsis: prognostic value of TIMP-1 in severe sepsis. Scand J Infect Dis 2006, 38:867-872. 10.1080/00365540600702058, 17008230.
10. Nakamura T, Ebihara I, Shimada N, Shoji H, Koide H. Modulation of plasma metalloproteinase-9 concentrations and peripheral blood monocyte mRNA levels in patients with septic shock: effect of fiber-immobilized polymyxin B treatment. Am J Med Sci 1998, 316:355-360. 10.1097/00000441-199812000-00001, 9856688.
11. Harbarth S, Holeckova K, Froidevaux C, Pittet D, Ricou B, Grau GE, Vadas L, Pugin J. Diagnostic value of procalcitonin, interleukin-6 and interleukin-8 in critically ill patients admitted with suspected sepsis. Am J Respir Crit Care Med 2001, 164:396-402.
12. Castelli GP, Prognani C, Meisner M, Stuani A, Bellomi D, Sgarbi L. Procalcitonin and C-reactive protein during systemic inflammatory response syndrome, sepsis and organ dysfunction. Crit Care 2004, 8:R234-R240. 522844, 15312223, 10.1186/cc2877.
13. Clech C, Ferriere F, Karoubi P, Fosse JP, Cupa M, Hoang P, Cohen Y. Diagnostic and prognostic value of procalcitonin in patients with septic shock. Crit Care Med 2004, 32:1166-1169. 10.1097/01.CCM.0000126263.00551.06, 15190968.
14. Roch A, Allardet-Servent J, Michelet P, Oddoze C, Forel JM, Barrau K, Loundou A, Perrin G, Auffray JP, Portugal H, Papazian L. NH2 terminal pro-brain natriuretic peptide plasma level as an early marker of prognosis and cardiac dysfunction in septic shock patients. Crit Care Med 2005, 33:1001-1007. 10.1097/01.CCM.0000162561.82012.E9, 15891328.
15. Gibot S, Pe LR, Bollaert PE, Kolopp-Sarda MN, Béné MC, Faure GC, Lévy B. Surface triggering receptor expressed on myeloid cells 1 expression patterns in septic shock. Intensive Care Med 2005, 31:594-597. 10.1007/s00134-005-2572-x, 15754199.
16. Lalu MM, Gao CQ, Schulz R. Matrix metalloproteinase inhibitors attenuate endotoxemia induced cardiac dysfunction: a potential role for MMP-9. Mol Cell Biochem 2003, 251:61-66. 10.1023/A:1025417529167, 14575305.